Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate

Zagazig University

Status and phase: Completed; Early Phase 1

Conditions: Glaucoma

Treatments: Drug: Latanoprost (Xalatan); Drug: Brimonidine 0.2 %

Study type: Interventional

Funder types: Other

Identifiers

NCT06730516

#454/25-June-2024.

Zagazig University (Registry Identifier)

Details and patient eligibility

About

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

Full description

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral POAG equally divided into two groups with 28 patients in each group. The whole VD was increased and also increased in all four nasal, temporal, superior, and inferior quadrants around optic disc from the initial vessel density before treatment (p<0.001) in both groups significantly with superior improvement in group (1) compared to group (2) that was statistically significant

Enrollment: 56 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age more than 18 years newly diagnosed naive patients with POAG

Exclusion criteria

• optic nerve lesions other than glaucomatous changes patients with previous glaucoma surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

56 participants in 2 patient groups

Latanoprost (Xalatan)

Experimental group

Description:

Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 %

Treatment:

Drug: Latanoprost (Xalatan)

Brimonidine 0.2%

Experimental group

Description:

24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2)

Treatment:

Drug: Brimonidine 0.2 %